ArticleTranslational cancer research2020

Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents.

Guangdi WangPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.